# Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors

> **NCT07743827** · NA · RECRUITING · sponsor: **Alexandria University** · enrollment: 90 (estimated)

## Conditions studied

- Olanzapine
- Breast Cancer
- Dexamethasone

## Interventions

- **DRUG:** Pantoprazole
- **DRUG:** olanzapine
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07743827
- **Lead sponsor:** Alexandria University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-10
- **Primary completion:** 2027-09-29
- **Final completion:** 2027-10-15
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743827, "Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*